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Leucine-rich repeat kinase 2 (LRRK2) mutation is the most common cause of genetic-related parkin-
sonism and is usually associated with Lewy body pathology; however, tau, a-synuclein, and ubiquitin
pathologies have also been reported. We report the case of a patient carrying the LRRK2 G2019S mutation
and a novel heterozygous variant c.370C>G, p.Q124E in exon 4 of the microtubule-associated protein tau
(MAPT). The patient developed parkinsonismwith good levodopa response in her 70s. Neuropathological
analysis revealed nigral degeneration and Alzheimer-type tau pathology without Lewy bodies. Immu-
nohistochemical staining using phospho-TDP-43 antibodies identiﬁed occasional TDP-43 pathology in
the hippocampus, temporal neocortex, striatum, and substantia nigra. However, TDP-43 pathology was
not identiﬁed in another 4 archival LRRK2 G2019S cases with Lewy body pathology available in the Queen
Square Brain Bank. Among other published cases of patients carrying LRRK2 G2019S mutation, only 3
were reportedly evaluated for TDP-43 pathology, and the results were negative. The role of the MAPT
variant in the clinical and pathological manifestation in LRRK2 cases remains to be determined.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Among the 5 identiﬁed pathogenic leucine-rich repeat kinase
2 (LRRK2) mutations, G2019S is the most common, and accounts for
1% of sporadic Parkinson’s disease and 4% of hereditary parkin-
sonism worldwide (Healy et al., 2008). Clinical presentation of
LRRK2 mutation resembles idiopathic Parkinson’s disease but may
be associatedwith amore benign disease course (Healy et al., 2008).
Most patients with LRRK2 mutation exhibit neuropathological
features consistent with typical Lewy body Parkinson’s disease
(Gilks et al., 2005; Khan et al., 2005; Zimprich et al., 2004); however,
“pure” nigral degeneration, tau, a-synuclein, or ubiquitin patholo-
gies resembling progressive supranuclear palsy (PSP), multiple
system atrophy, and frontotemporal lobar degeneration with
ubiquitin-positive inclusions (FTLD-U) have also been reported
(Dachsel et al., 2007; Gaig et al., 2008; Giasson et al., 2006;
Hasegawa et al., 2009; Rajput et al., 2006; Zimprich et al., 2004).
Ubiquitinated TAR DNA-binding proteine43 (TDP-43) is a majork for Neurological Disorders,
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r Inc. Open access under CC BY licensedisease protein in FTLD and amyotrophic lateral sclerosis (ALS) and
can occasionally be observed in Lewy body disorders and tauo-
pathies (Mackenzie et al., 2010; Neumann et al., 2006; Sreedharan
et al., 2008). Recently, TDP-43erelated pathology was reported in
3 patients carrying LRRK2 mutations (p.R1441C, p.R793M and
L1165P) (Covy et al., 2009; Wider et al., 2010). Here, we report
a patient with a clinical diagnosis of Parkinson’s disease, who in
post-mortem was found to have nigral degeneration without Lewy
body pathology, and was also shown to carry the LRRK2 G2019S
mutation and a novel heterozygous variant c.370C>G, p.Q124E in
exon 4 of the microtubule-associated protein tau (MAPT).2. Methods
2.1. Case selection and genetic analysis
Genomic DNA was extracted from frozen brain tissue of these
cases, and Sanger sequencing was performed according to standard
procedures as previously described (Kara et al., 2012). As part of an
ongoing clinicopathological study to evaluate archival cases with
post-encephalitic parkinsonism (PEP) and unclassiﬁable tauopathy
at the Queen Square Brain Bank for Neurological Disorders (QSBB),
we sequenced LRRK2 (exons 24, 25, 27, 29, 35, 36, 41, and 48), PARK2
andMAPT genes in 13 cases. PARK2was chosen because it can cause.
Fig. 1. Diagram of the MAPT gene depicting the location of the 3 rare variants reported
to date to be associated with tau pathology. The novel variant c.370C>G is indicated
with a black arrow on the chromatogram above the p.Q124E variant.
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(Doherty et al., 2013), whereas LRRK2 mutations are more
commonly associated with Lewy body pathology (Wider et al.,
2010). MAPT gene was sequenced because of the presence of tau
pathology in these cases. From this cohort, we recently published
our ﬁndings of the rareMAPT p.A152T variant as a risk factor for the
development of tauopathies (Kara et al., 2012). MRC-Holland
(Amsterdam, the Netherlands) multiplex ligation-dependent probe
ampliﬁcation (MLPA) kits (P051, P052) were used for copy-number
analysis of the following genes: PARK2 6q25.2, SNCA 4q21, Pink1,
Park7 1p36, UCHL1 4p14, GCH1 14q22.1, and LRRK2 12q12. Muta-
tions and variants identiﬁed in MAPT, LRRK2, and PARK2 were
named based on transcripts with accession numbers NM_005910.5/
NP_005901.2, NM_198578.3/NP_940980.3, and NM_004562.2/
NP_004553.2, respectively. MAPT haplotypes were determined by
the genotype of the H1/H2-tagging SNP rs1052553 (Hayesmoore
et al., 2009). The TDP-43 gene was sequenced in the present case
with TDP-43 pathology. In 4 other cases with proven LRRK2 G2019S
mutations and Lewy body pathology available in the QSBB (Gilks
et al., 2005), sequencing of the MAPT gene was performed.
Subjects in this report had provided written consent to perform
neuropathological and genetic studies. All protocols of brain dona-
tion had been approved by a London Research Ethics Committee,
and tissue is stored for research at the QSBB with a license from the
Human Tissue Authority. This research was approved by the Tissue
Request Committee of the QSBB.
2.2. Neuropathology
Following the QSBB protocols, the brains were divided mid-
sagittally post mortem. One-half of the brain was immediately
frozen and stored at 80 C, and the other half was immersed
and ﬁxed in 10% neutral formalin for 3 weeks. After slicing and
sampling the brain, tissue blocks were processed using standard
protocols. We performed hematoxylin and eosin, Luxol fast blue/
cresyl violet, and Congo red staining on 7-mm-thick sections,
and also used the modiﬁed Bielschowsky and Gallyas silver
impregnation methods. Immunohistochemistry with antibodies to
phospho-tau (AT8 clone recognizing Ser202/Thr205; BioScience
Life Sciences; 1:600), 3-repeat (3R) and 4-repeat (4R) tau isoforms
(Upstate/Millipore; 3R tau: RD3; 1:2000; 4R tau: RD4; 1:200)
(de Silva et al., 2003), Ab (Dako; 6F/3D; 1:100), ubiquitin, p62, TDP,
p-TDP, a-synuclein (Vector Laboratories; KM51; 1:50) and phospho-
a-synuclein (recognizing Ser 129; Abcam-ab59264; rabbit poly-
clonal) was carried out using a standard avidinebiotin method.
In 4 other cases with proven LRRK2 G2019S mutations and Lewy
body pathology available in the QSBB (Gilks et al., 2005), immuno-
histochemistry staining using antibody to phospho-TDP-43 (p-TDP)
was carried out in the hippocampus, amygdala, and upper midbrain
blocks.
To assess whether the neuronal loss in the substantia nigra
pars compacta (SNpc) identiﬁed in the LRRK2 case was related to
the genetic mutation or to its Alzheimer’s related pathology, we
performed semi-quantitative assessment of nigral cell loss in 12
randomly selected cases with conﬁrmed pathological diagnosis of
Alzheimer’s disease (AD).
3. Results
3.1. Genetic analysis
Of the 13 cases with PEP and unclassiﬁable tauopathy we
identiﬁed 1 case with both LRRK2 G2019S mutation and a hetero-
zygous variant in MAPT exon 4 (c.370C>G, p.Q124E) (Fig. 1). The
MAPT p.Q124E variant is absent in all control subjects in the publicdatabases (N ¼ 6568, of which 3913 are caucasians), which include,
Ensemble (http://useast.ensembl.org/index.html) and Exome Var-
iant Server (Exome Variant Server, NHLBI GO Exome Sequencing
Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/)
[(1,2013) accessed]) (see Supplementary Table 1); this variant is
also absent in the 4 LRRK2 cases with Lewy body pathology. The
MAPT haplotype of this patient was H1/H2. PARK2 and TDP-43
sequencings in this case were negative. A dosage study using MLPA
was negative for all analyzed genes including PARK2 and LRRK2.
3.2. Case report
The British white woman who carried the LRRK2 G2019S
mutation and the heterozygous p.Q124E MAPT variant, developed
right-hand tremor at age 73 years. She had mild bradykinesia and
rigidity and was diagnosed with idiopathic Parkinson’s disease. She
was initially started on an anticholinergic medication; 5 years later,
levodopa therapy was administered and titrated to 1000 mg/day,
with a good response. She had no cognitive impairment. Her
motor symptoms gradually deteriorated. She reported wearing-off
symptoms but never had any dyskinesia. In the last year of life,
she had balance difﬁculty, multiple falls and required a rollator to
mobilize. She died at age 85. There was no family history of any
movement or neurological disorders.
Neuropathological analysis conﬁrmed an overall moderate
degree of neuronal loss in the SNpc except in the ventrolateral
tier, where severe neuronal loss was found (Fig. 2). There were no
Lewy bodies on a-synuclein or phospho-a-synuclein immuno-
histochemistry. There were sparse tau-positive neuropil threads
(NTs) in the frontal and parietal cortices; sparse NTs, neuroﬁ-
brillary tangles (NFTs), and pre-tangles (PreTs) in the CA1 and
CA4 hippocampal subregions; mild PreTs, moderate numbers of
NPs, NFTs and NTs in the subiculum; severe NFTs, NTs, and PreTs
in the entorhinal cortex and very sparse NTs in the striatum
(Fig. 2). All tau inclusions were both 3R- and 4R-tau positive. The
subthalamic nucleus was preserved, and no tau pathology was
noted.
Ab immunohistochemistry demonstrated parenchymal deposi-
tion in the cerebral cortex, hippocampus, and striatum corre-
sponding to Thal phase score of 3 (Thal et al., 2002), whereas the
distribution of tau pathology corresponded to Braak and Braak stage
III (Braak et al., 2006). Using the Consortium to Establish a Registry
for Alzheimer’s disease (CERAD) criteria (Mirra et al., 1991), the NP
score was “sparse” in the temporal cortex, “moderate” in the frontal
cortex, and “sparse” in the parietal cortex. These results gave a “low”
likelihood of AD, according to the National Institute on Ageing
(NIA)/Reagan Institute of the Alzheimer Association Consensus
Recommendations for the Postmortem Diagnosis of Alzheimer’s
disease,1997 (NIA-Reagan criteria) (Hyman and Trojanowski,1997),
and “intermediate” level of AD pathologic change (A2, C2, B2)
according to the 2012 guideline (Hyman et al., 2012).
TDP-43 and p-TDP-43 immunohistochemistry showed numerous
ﬁne thread-like processes and few coarser neurites in the CA1
hippocampal subregion and subiculum. In the amygdala and the
temporal and frontal cortices, there were occasional NCIs and few
Fig. 2. Key neuropathological ﬁndings in the present case. Severe loss of neuromelanin-containing neurons in the ventrolateral tier of the substantia nigra (arrows), as well as gliosis
and free pigment (arrowheads) (A); Abundant tau-positive neuroﬁbrillary tangles, neuropil threads, and pre-tangles in the entorhinal cortex (B); phospho-TDP-43 (p-TDP)
immunoreactive neuronal cytoplasmic inclusions (NCIs), neurites, and a skein-like structure (inset) in the substantia nigra (C); and numerous p-TDPepositive ﬁne thread-like
processes, few coarser neurites, round, dot-like structures, and a “cat’s-eye” neuronal intranuclear inclusion (NII) (inset) in the subiculum (D). A, hematoxylin and eosin stain-
ing; B, AT8; and C and D, phospho-TDP-43 immunostaining.
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subiculum, striatum, and SN, and skein-like NCIs in the SN (Fig. 2).
There was no hippocampal sclerosis. No a-synuclein immu-
noreactive inclusions, argyrophilic grains, cerebral amyloid angi-
opathy (CAA), or vascular pathology was observed. No P62-positve
“star-shaped” inclusion in the hippocampus or small “dot-like”
structures in the cerebellar granule cells were observed.
3.3. Findings in other LRRK2 G2019S cases
In 4 other cases available in the QSBB with proven LRRK2
G2019S mutation, no TDP-43erelated pathology was observed in
the hippocampus or amygdala. Sequencing of the MAPT gene did
not reveal any abnormal ﬁnding.
3.4. Nigral degeneration in AD control cases
In the 12 randomly selected cases with conﬁrmed pathological
diagnosis of Alzheimer’s disease (NIA/Reagan “high” likelihood of
AD), nigral cell loss was, at most, mild, as evidenced by regional
pigment incontinence in the SNpc.
4. Discussion
LRRK2 G2019S mutation is commonly associated with Lewy
body pathology. Of the 22 published post-mortem cases with this
mutation, only 4 cases had an absence of Lewy bodies. Rajput et al
reported a case with slow, progressive, nonelevodopa-responsive
parkinsonism and tau-positive NFTs resembling the neuropa-
thology of PSP (Rajput et al., 2006), Giasson et al and Gaig et al each
reported a case with classical tremor-dominant parkinsonism and
pure nigral degeneration (Gaig et al., 2008; Giasson et al., 2006),
and, Dachsel et al reported a case with dementia and tremor and
pathology consisted of FTLDwith ubiquitinated neuronal inclusions(FTLD-U) (Dachsel et al., 2007). On the other hand, pleomorphic
pathologies including a-synuclein, tau, and ubiquitin seem to be
more commonly associatedwith other pathogenic LRRK2mutations
(Hasegawa and Kowa, 1997; Hasegawa et al., 2009; Santpere and
Ferrer, 2009; Wszolek et al., 1997, 2004; Zimprich et al., 2004).
We report a casewith LRRK2G2019Smutation clinically diagnosed
as Parkinson’s disease, with good levodopa response, in which neu-
ropathological analysis revealed nigral degenerationwith an absence
of Lewy bodies, Alzheimer-type tau, and TDP-43 pathologies. Inter-
estingly, this patient was also found to carry a novel p.Q124E MAPT
variant. Prompted by the TDP-43 pathology, we screened this case
for TDP-43 mutations, which were negative. We then surveyed for
TDP-43 pathology in another 4 archival QSBB cases with LRRK2
G2019S mutation and Lewy body pathology, and the ﬁndings were
negative. These 4 LRRK2 G2019S cases were also negative for patho-
genic mutations or novel variants in MAPT. To date, only 3 cases
with LRRK2 mutation have been reported to have TDP-43erelated
pathology (p.R1441C, p.R793M, and L1165P) (Covy et al., 2009;
Zimprich et al., 2004), none of which had the G2019Smutation. Only
3 other published cases carrying the LRRK2 G2019S mutation
were evaluated for TDP-43 pathology (Giasson et al., 2006) but no
TDP-43epositive inclusions were observed (Covy et al., 2009).
The discovery of TDP-43 in 2006 as a major disease protein in
FTLD and ALS led to the introduction of TDP-43 immunohisto-
chemistry into the routine diagnostic protocols of brain banks in
the last few years. It is therefore likely that other reported LRRK2
cases with ubiquitin pathology may also have TDP-43 inclusions
and will warrant comprehensive assessment (Dachsel et al., 2007;
Wszolek et al., 1997, 2004; Zimprich et al., 2004). In addition to
FTLD-TDP and ALS, TDP-43 inclusions can sometimes be detected in
other neurodegenerative diseases including AD, Lewy body disor-
ders, and primary tauopathies including corticobasal degeneration,
PSP, parkinsonism-dementia complex of Guam, and dementia
pugilistica (Arai et al., 2009; Hasegawa et al., 2007; King et al., 2010;
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et al., 2010). The cause andmechanism of TDP-43 in tauopathies are
not known, but it has been postulated that tau aggregates may
promote aggregation of TDP-43 through cross-seeding (Morales
et al., 2009; Uryu et al., 2008). TDP-43 immunoreactivity may
modify clinical features in AD and other types of dementia (Josephs
et al., 2008; Lashley et al., 2011), and is also closely associated with
hippocampal sclerosis (Amador-Ortiz et al., 2007; Josephs et al.,
2008). It remains to be determined whether TDP-43 protein plays
a role in inﬂuencing the clinical features in LRRK2 cases. As in Lewy-
body Parkinson’s disease, nigral degeneration is a typical ﬁnding in
LRRK2 mutation and is considered to be the pathological substrate
of clinical parkinsonism in these patients (Wider et al., 2010).
Although previous studies have shown a correlation between nigral
pathology and extrapyramidal symptoms in AD (Burns et al., 2005),
our screening of 12 randomly selected AD cases did not reveal
signiﬁcant nigral cell loss, in contrast to the present LRRK2 case. It is
therefore unlikely that the modest Alzheimer-type tau pathology in
this case would explain the extent of the nigral cell loss.
The pleomorphic pathologies in LRRK2 mutation supports
the notion that LRRK2 acts upstream from the pathway of other
proteins implicated in neuronal death; and it is likely that ge-
netic and environmental factors then inﬂuence the type of pro-
teinopathy that eventually develops in the individual, whether it is
a-synuclein, tau, or ubiquitin pathology (Wider et al., 2010). The
novel MAPT variant identiﬁed in our case is located in a region of
the protein far from microtubule-binding domains and does not
have an obvious role in the molecule’s function. A similar variant
was also recently reported in exon 7 of the MAPT gene (Coppola
et al., 2012; Cruchaga et al., 2012; Jin et al., 2012; Kara et al.,
2012), and a rare variant p.A239T in exon 8 (NM_005910.5) was
found in a carrier of a C9orf72 repeat expansion (King et al., 2013)
(Fig. 1). Interestingly, these 3 rare variants all localize in an
uncharacterized region of the MAPT protein in cases with unex-
pected tau pathology, which supports the speculation that these
variants may have a disease-modifying role and may predispose
the individual to tau pathology (Coppola et al., 2012; Devine and
Lewis, 2008; Gan-Or et al., 2012; Kara et al., 2012). However, the
precise mechanism of this relation is far from clear, and our genetic
ﬁndings in this case serve as an interesting observation rather than
yielding a deﬁnitive conclusion. It is noteworthy that, in LRRK2
cases with atypical clinical presentation and/or unusual patholo-
gies, one should also consider the possibility of a coincidental
neurodegenerative process with a non-penetrant LRRK2 mutation
(Goldwurm et al., 2011; Sierra et al., 2011; Xiromerisiou et al.,
2012).
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